MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
HrFlow.ai Secures 7 Million Dollars (Pre-Series A) to Become the Global Standard for Artificial Intelligence (AI) Applied to HR Data24.4.2026 01:40:00 CEST | Press release
PARIS, FR / ACCESS Newswire / April 23, 2026 / 1. Fundraising and Objectives HrFlow.ai, a pioneer in Artificial Intelligence applied to Human Resources data, announces its second fundraising round of $7M (pre-Series A) today. This financing brings the company's total capital raised to $10 million. This new capital injection is designed to accelerate the company's core mission: building the Data & AI infrastructure of the labor market. The round is led by 115K, La Banque Postale's venture capital fund, and EmergingTech Ventures (EmTech), alongside the company's existing investors including Xavier Niel (Free, Kima, Station F), Jean-Baptiste Rudelle (Criteo), Romain Niccoli (Pigment, Criteo), Franck Le Ouay (LIFEN, Criteo), Flavien Kulawik (KLB), Allen Penn (Uber), Dominique Vidal (Index Ventures), Thibaud Elzière (Hexa, Fotolia). Building on rigorous execution and proven capital efficiency since its first funding round of $2.3M in 2018, HrFlow.ai now generates a margin of approximately 2
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance22.4.2026 16:00:00 CEST | Press release
Builds on December 2025 Content Licensing Patents and Carbon Credit Tokenization Grant; Strengthens IP Moat Across Data Valuation, Virtual Funding, and Tokenized Tax Prep PHILADELPHIA, PA / ACCESS Newswire / April 22, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent. Key Highlights for Investors One newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated d
Karbon-X Highlights SkyXero on Earth Day, Bringing Real-Time Climate Action to Travel22.4.2026 15:15:00 CEST | Press release
Company underscores leadership use and introduces matched contribution initiative to support verified climate projects. CALGARY, AB / ACCESS Newswire / April 22, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today marked Earth Day by highlighting SkyXero, its mobile application designed to help individuals understand and act on the emissions associated with their air travel. As global travel continues to increase, flight emissions remain one of the least visible and least understood components of individual environmental impact. SkyXero addresses this gap by enabling users to calculate emissions associated with any commercial flight and support verified climate projects such as reforestation, renewable energy, and carbon reduction initiatives. To reinforce its commitment to practical climate accountability, Karbon-X has applied SkyXero internally across its l
DOJO AI Raises $6M to Power Agentic Marketing Platform, Transforming Data Into Business Impact22.4.2026 14:00:00 CEST | Press release
Backed by Armilar and Heartfelt VC, the company serves over 100 customers across the U.S. and U.K., including CoinDesk, Morningstar, Broadvoice, PensionBee, CovertSwarm and Refine Labs LONDON, UK AND LISBON, PORTUGAL / ACCESS Newswire / April 22, 2026 / DOJO AI, the intelligent marketing system that brings a new class of integrated AI to marketing teams, today announced a $6 million seed round at a $30 million valuation. The round was led by Armilar, with participation from Heartfelt VC. The funding will support continued product development and accelerated expansion in the United States. DOJO AI introduces a new paradigm for marketing technology, powering what the industry is beginning to call agentic marketing: a system where AI agents don't just report on performance but take action on it. The platform watches paid and organic campaigns around the clock, audits SEO and Answer Engine Optimization visibility continuously, generates brand-aligned content, and feeds every outcome back i
GoodData Launches Agent Builder for Enterprise AI22.4.2026 12:00:00 CEST | Press release
Enterprises can now deploy governed analytics agents in minutes, with full control over configuration, context, and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 22, 2026 / GoodData, the AI-powered analytics and decision intelligence platform, today announced the launch of Agent Builder, a new capability that expands its platform with a dedicated environment for building, configuring, and scaling AI agents across the enterprise. Agent Builder enables organizations to move beyond single-purpose AI assistants and instead deploy multiple, purpose-built analytics agents that can be precisely configured, governed, and scaled across customers, workspaces, and user groups. The launch addresses a growing enterprise challenge: while organizations are rapidly moving from experimentation to production with AI agents, consistent, secure, and scalable deployment across business units remains difficult without significant custom engineering. From Experimentation to Enterprise Scale While most a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom